Advertisement

The Role of Tomato Lycopene in Cancer Prevention

  • Joseph LevyEmail author
  • Shlomo Walfisch
  • Andrea Atzmon
  • Keren Hirsch
  • Marina Khanin
  • Karin Linnewiel
  • Yael Morag
  • Hagar Salman
  • Anna Veprik
  • Michael Danilenko
  • Yoav Sharoni
Chapter
Part of the Diet and Cancer book series (DICA, volume 2)

Abstract

The role of the tomato carotenoid lycopene in cancer prevention has gained considerable interest in recent years. Most studies reported an inverse association between tomato intake or blood lycopene level and the risk of various types of cancer. This is supported by mechanistic studies with various cell culture and animal models. The biochemical processes involved in the chemoprotective effects of lycopene and other carotenoids are not completely understood. In this review we will primarily address the mechanisms proposed for the cancer preventive activity of tomato lycopene, focusing on the induction of phase II enzymes and the inhibition of growth factors, such as insulin-like growth factor, and sex hormones such as estrogens and androgens.

Keywords

Tomato lycopene Phase II enzymes Growth factors Sex hormones Chemoprevention 

References

  1. Albanes D, Heinonen OP, Taylor PR et al (1996) Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 88:1560–1570PubMedCrossRefGoogle Scholar
  2. Amir H, Karas M, Giat J et al (1999) Lycopene and 1,25-dihydroxyvitamin-D3 cooperate in the inhibition of cell cycle progression and induction of differentiation in HL-60 leukemic cells. Nutr Cancer 33:105–112PubMedCrossRefGoogle Scholar
  3. Anderson ML (2005) A preliminary investigation of the enzymatic inhibition of 5alpha-reduction and growth of prostatic carcinoma cell line LNCap-FGC by natural astaxanthin and Saw Palmetto lipid extract in vitro. J Herb Pharmacother 5:17–26PubMedGoogle Scholar
  4. Astorg P, Berges R, Suschetet M (1994) Induction of gamma GT- and GST-P positive foci in the liver of rats treated with 2-nitropropane or propane 2-nitronate. Cancer Lett 79:101–106PubMedCrossRefGoogle Scholar
  5. Aust O, Ale-Agha N, Zhang L et al (2003) Lycopene oxidation product enhances gap junctional communication. Food Chem Toxicol 41:1399–1407PubMedCrossRefGoogle Scholar
  6. Balogun E, Hoque M, Gong P et al (2003) Curcumin activates the heme oxygenase-1 gene via regulation of Nrf2 and the antioxidant responsive element. Biochem J 371:887–895PubMedCrossRefGoogle Scholar
  7. Ben-Dor A, Steiner M, Gheber L et al (2005) Carotenoids activate the antioxidant response element transcription system. Mol Cancer Ther 4:177–186PubMedGoogle Scholar
  8. Bohm V, Bitsch R (1999) Intestinal absorption of lycopene from different matrices and interactions to other carotenoids, the lipid status, and the antioxidant capacity of human plasma. Eur J Nutr 38:118–125PubMedCrossRefGoogle Scholar
  9. Boileau TW, Liao Z, Kim S et al (2003) Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. J Natl Cancer Inst 95:1578–1586PubMedCrossRefGoogle Scholar
  10. Breinholt V, Lauridsen ST, Daneshvar B et al (2000) Dose-response effects of lycopene on selected drug-metabolizing and antioxidant enzymes in the rat. Cancer Lett 154:201–210PubMedCrossRefGoogle Scholar
  11. Buckley MF, Sweeney KJ, Hamilton JA et al (1993) Expression and amplification of cyclin genes in human breast cancer. Oncogene 8:2127–2133PubMedGoogle Scholar
  12. Campbell JK, Stroud CK, Nakamura MT et al (2006) Serum testosterone is reduced following short-term phytofluene, lycopene, or tomato powder consumption in f344 rats. J Nutr 136:2813–2819PubMedGoogle Scholar
  13. Canene-Adams K, Lindshield BL, Wang S et al (2007) Combinations of tomato and broccoli enhance antitumor activity in dunning r3327-h prostate adenocarcinomas. Cancer Res 67:836–843PubMedCrossRefGoogle Scholar
  14. Carroll JS, Prall OW, Musgrove EA et al (2000) A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. J Biol Chem 275:38221–38229PubMedCrossRefGoogle Scholar
  15. Chalabi N, Le Corre L, Maurizis JC et al (2004) The effects of lycopene on the proliferation of human breast cells and BRCA1 and BRCA2 gene expression. Eur J Cancer 40:1768–1775PubMedCrossRefGoogle Scholar
  16. Chalabi N, Maurizis JC, Le Corre L et al (2005) Quantification by affinity perfusion chromatography of phosphorylated BRCAl and BRCA2 proteins from tumor cells after lycopene treatment. J Chromatogr B Analyt Technol Biomed Life Sci 821:188–193PubMedCrossRefGoogle Scholar
  17. Chan JM, Stampfer MJ, Giovannucci E et al (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279:563–566PubMedCrossRefGoogle Scholar
  18. Chiang HS, Wu WB, Fang JY et al (2007) Lycopene inhibits PDGF-BB-induced signaling and migration in human dermal fibroblasts through interaction with PDGF-BB. Life Sci 81:1509–1517PubMedCrossRefGoogle Scholar
  19. Clark PE, Hall MC, Borden LS et al (2006) Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology 67:1257–1261PubMedCrossRefGoogle Scholar
  20. Cook NR, Le IM, Manson JE et al (2000) Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians’ Health Study (United States). Cancer Causes Control 11:617–626PubMedCrossRefGoogle Scholar
  21. Cui Y, Shikany JM, Liu S et al (2008) Selected antioxidants and risk of hormone receptor-defined invasive breast cancers among postmenopausal women in the Women’s Health Initiative Observational Study. Am J Clin Nutr 87:1009–1018PubMedGoogle Scholar
  22. Cummings SR, Eckert S, Krueger KA et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189–2197PubMedCrossRefGoogle Scholar
  23. Daughaday WH, Deuel TF (1991) Tumor secretion of growth factors. Endocrinol Metab Clin North Am 20:539–563PubMedGoogle Scholar
  24. Deng CX, Brodie SG (2000) Roles of BRCA1 and its interacting proteins. Bioessays 22:728–737PubMedCrossRefGoogle Scholar
  25. Dingley KH, Ubick EA, Chiarappa-Zucca ML et al (2003) Effect of dietary constituents with chemopreventive potential on adduct formation of a low dose of the heterocyclic amines PhIP and IQ and phase II hepatic enzymes. Nutr Cancer 46:212–221PubMedCrossRefGoogle Scholar
  26. Dinkova-Kostova AT, Holtzclaw WD, Cole RN et al (2002) Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci USA 99:11908–11913PubMedCrossRefGoogle Scholar
  27. Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–1467CrossRefGoogle Scholar
  28. Ferrucci L, Perry JR, Matteini A et al (2009) Common variation in the beta-carotene 15,15'-monooxygenase 1 gene affects circulating levels of carotenoids: a genome-wide association study. Am J Hum Genet 84:123–133PubMedCrossRefGoogle Scholar
  29. Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388PubMedCrossRefGoogle Scholar
  30. Gaudet MM, Britton JA, Kabat GC et al (2004) Fruits, vegetables, and micronutrients in relation to breast cancer modified by menopause and hormone receptor status. Cancer Epidemiol Biomarkers Prev 13:1485–1494PubMedGoogle Scholar
  31. Giovannucci E (1999) Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst 91:317–331PubMedCrossRefGoogle Scholar
  32. Giovannucci E (2005) Tomato products, lycopene, and prostate cancer: A review of the epidemiological literature. J Nutr 135:2030S–2031SPubMedGoogle Scholar
  33. Giovannucci E, Pollak M, Liu Y et al (2003) Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev 12:84–89PubMedGoogle Scholar
  34. Gradelet S, Astorg P, Leclerc J et al (1996) Effects of canthaxanthin, astaxanthin, lycopene and lutein on liver xenobiotic-metabolizing enzymes in the rat. Xenobiotica 26:49–63PubMedCrossRefGoogle Scholar
  35. Graydon R, Gilchrist SE, Young IS et al (2007) Effect of lycopene supplementation on insulin-like growth factor-1 and insulin-like growth factor binding protein-3: a double-blind, placebo-controlled trial. Eur J Clin Nutr 61:1196–1200PubMedCrossRefGoogle Scholar
  36. Greenlee RT, Hill-Harmon MB, Murray T et al (2001) Cancer statistics 2001. CA Cancer J Clin 51:15–36PubMedCrossRefGoogle Scholar
  37. Gunnell D, Oliver SE, Peters TJ et al (2003) Are diet-prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men. Br J Cancer 88:1682–1686PubMedCrossRefGoogle Scholar
  38. Heinonen OP, Huttunen JK, Albanes D et al (1994) Effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330:1029–1035CrossRefGoogle Scholar
  39. Henderson BE, Ross R, Bernstein L (1988) Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 48:246–253PubMedGoogle Scholar
  40. Herzog A, Siler U, Spitzer V et al (2005) Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate. FASEB J 19:272–274PubMedGoogle Scholar
  41. Hirsch K, Atzmon A, Danilenko M et al (2007) Lycopene and other carotenoids inhibit estrogenic activity of 17β-estradiol and genistein in cancer cells. Breast Cancer Res Treat 104:221–230PubMedCrossRefGoogle Scholar
  42. Holmes MD, Pollak MN, Willett WC et al (2002) Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 11:852–261PubMedGoogle Scholar
  43. Hu KQ, Liu C, Ernst H et al (2006) The biochemical characterization of ferret carotene-9', 10'-monooxygenase catalyzing cleavage of carotenoids in vitro and in vivo. J Biol Chem 281:19327–19338PubMedCrossRefGoogle Scholar
  44. Huang CS, Liao JW, Hu ML (2008) Lycopene inhibits experimental metastasis of human hepatoma SK-Hep-1 cells in athymic nude mice. J Nutr 138:538–543PubMedGoogle Scholar
  45. Huggins C, Hodges CV (1972) Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22:232–240PubMedCrossRefGoogle Scholar
  46. IARC Handbook of Cancer Prevention (1998) Carotenoids, WHO PressGoogle Scholar
  47. Iqbal M, Sharma SD, Okazaki Y et al (2003) Dietary supplementation of curcumin enhances antioxidant and phase II metabolizing enzymes in ddY male mice: possible role in protection against chemical carcinogenesis and toxicity. Pharmacol Toxicol 92:33–38PubMedCrossRefGoogle Scholar
  48. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96PubMedCrossRefGoogle Scholar
  49. Kaarbo M, Klokk TI, Saatcioglu F (2007) Androgen signaling and its interactions with other signaling pathways in prostate cancer. Bioessays 29:1227–1238PubMedCrossRefGoogle Scholar
  50. Kanagaraj P, Vijayababu MR, Ravisankar B et al (2007) Effect of lycopene on insulin-like growth factor-I, IGF binding protein-3 and IGF type-I receptor in prostate cancer cells. J Cancer Res Clin Oncol 133:351–359PubMedCrossRefGoogle Scholar
  51. Karas M, Kleinman D, Danilenko M et al (1995) Components of the IGF system mediate the opposing effects of tamoxifen on endometrial and breast cancer cell growth. Prog Growth Factor Res 6:513–520PubMedCrossRefGoogle Scholar
  52. Karas M, Amir H, Fishman D et al (2000) Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells. Nutr Cancer 36:101–111PubMedCrossRefGoogle Scholar
  53. Khachik F, Carvalho L, Bernstein PS et al (2002) Chemistry, distribution, and metabolism of tomato carotenoids and their impact on human health. Exp Biol Med (Maywood) 227:845–851Google Scholar
  54. Kong AN, Owuor E, Yu R et al (2001) Induction of xenobiotic enzymes by the map kinase pathway and the antioxidant or electrophile response element (ARE/EpRE). Drug Metab Rev 33:255–271PubMedCrossRefGoogle Scholar
  55. Krinsky NI, Johnson EJ (2005) Carotenoid actions and their relation to health and disease. Mol Aspects Med 26:459–516PubMedCrossRefGoogle Scholar
  56. Kwak MK, Egner PA, Dolan PM et al (2001) Role of phase 2 enzyme induction in chemoprotection by dithiolethiones. Mutat Res 480–481:305–315PubMedGoogle Scholar
  57. LeRoith D, Roberts CT Jr (2003) The insulin-like growth factor system and cancer. Cancer Lett 195:127–137PubMedCrossRefGoogle Scholar
  58. Levy J, Bosin E, Feldman B et al (1995) Lycopene is a more potent inhibitor of human cancer cell proliferation than either α-carotene or β-carotene. Nutr Cancer 24:257–267PubMedCrossRefGoogle Scholar
  59. Levy J, Walfisch S, Walfisch Y et al (2008) Tomato Carotenoids and the IGF System in Cancer. In: Preedy V, Watson R (ed) Tomatoes and tomato products: nutritional, medicinal and therapeutic properties. Science, Enfield, USA 397–412Google Scholar
  60. Lian F, Smith DE, Ernst H et al (2007) Apo-10'-lycopenoic acid inhibits lung cancer cell growth in vitro, and suppresses lung tumorigenesis in the A/J mouse model in vivo. Carcinogenesis 28:1567–1574PubMedCrossRefGoogle Scholar
  61. Limpens J, Schroder FH, de Ridder CM et al (2006) Combined lycopene and vitamin E treatment suppresses the growth of PC-346C human prostate cancer cells in nude mice. J Nutr 136:1287–1293PubMedGoogle Scholar
  62. Linnewiel K, Hansgeorg E, Caris-Veyrat C et al (2009) Structure activity relationship of carotenoid derivatives in activation of the electrophile/antioxidant response element transcription system. Free Radic Biol Med. 47:659–667PubMedCrossRefGoogle Scholar
  63. Liu C, Lian F, Smith DE et al (2003) Lycopene supplementation inhibits lung squamous metaplasia and induces apoptosis via up-regulating insulin-like growth factor-binding protein 3 in cigarette smoke-exposed ferrets. Cancer Res 63:3138–3144PubMedGoogle Scholar
  64. Liu X, Allen JD, Arnold JT et al (2008) Lycopene inhibits IGF-I signal transduction and growth in normal prostate epithelial cells by decreasing DHT-modulated IGF-I production in co-cultured reactive stromal cells. Carcinogenesis 29:816–823PubMedCrossRefGoogle Scholar
  65. Martin D, Rojo AI, Salinas M et al (2004) Regulation of Heme Oxygenase-1 Expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J Biol Chem 279:8919–8929PubMedCrossRefGoogle Scholar
  66. Mucci LA, Tamimi R, Lagiou P et al (2001) Are dietary influences on the risk of prostate cancer mediated through the insulin-like growth factor system? BJU Int 87:814–820PubMedCrossRefGoogle Scholar
  67. Murakoshi M, Takayasu J, Kimura O et al (1989) Inhibitory effects of α-Carotene on proliferation of the human neuroblastoma cell line GOTO. J Natl Cancer Inst 81:1649–1652PubMedCrossRefGoogle Scholar
  68. Musgrove EA, Swarbrick A, Lee CS et al (1998) Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol Cell Biol 18:1812–1825PubMedGoogle Scholar
  69. Nahum A, Hirsch K, Danilenko M et al (2001) Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes. Oncogene 20:3428–3436PubMedCrossRefGoogle Scholar
  70. Nahum A, Zeller L, Danilenko M et al (2006) Lycopene inhibition of IGF-induced cancer cell growth depends on the level of cyclin D1. Eur J Nutr 45:275–282PubMedCrossRefGoogle Scholar
  71. Okuzumi J, Nishino H, Murakoshi M et al (1990) Inhibitory effects of fucoxanthin, a natural carotenoid, on N-myc expression and cell cycle progression in human malignant tumor cells. Cancer Lett 55:75–81PubMedCrossRefGoogle Scholar
  72. Olmedilla B, Granado F, Southon S et al (2002) A European multicentre, placebo-controlled supplementation study with alpha-tocopherol, carotene-rich palm oil, lutein or lycopene: analysis of serum responses. Clin Sci 102:447–456PubMedCrossRefGoogle Scholar
  73. Omenn GS, Goodman GE, Thornquist MD et al (1996) Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334:1150–1155PubMedCrossRefGoogle Scholar
  74. Paetau I, Khachik F, Brown ED et al (1998) Chronic ingestion of lycopene-rich tomato juice or lycopene supplements significantly increases plasma concentrations of lycopene and related tomato carotenoids in humans. Am J Clin Nutr 68:1187–1195PubMedGoogle Scholar
  75. Pastori M, Pfander H, Boscoboinik D et al (1998) Lycopene in association with alpha-tocopherol inhibits at physiological concentrations proliferation of prostate carcinoma cells. Biochem Biophys Res Commun 250:582–585PubMedCrossRefGoogle Scholar
  76. Planas Silva MD, Weinberg RA (1997) Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol 17:4059–4069PubMedGoogle Scholar
  77. Pourmand G, Salem S, Mehrsai A et al (2007) The risk factors of prostate cancer: a multicentric case-control study in Iran. Asian Pac J Cancer Prev 8:422–428PubMedGoogle Scholar
  78. Prakash P, Russell RM, Krinsky NI (2001) In vitro inhibition of proliferation of estrogen-dependent and estrogen-independent human breast cancer cells treated with carotenoids or retinoids. J Nutr 131:1574–1580PubMedGoogle Scholar
  79. Prochaska HJ, Talalay P (1988) Regulatory mechanisms of monofunctional and bifunctional anticarcinogenic enzyme inducers in murine liver. Cancer Res 48:4776–4782PubMedGoogle Scholar
  80. Riboli E, Norat T (2003) Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. Am J Clin Nutr 78:559S–569SPubMedGoogle Scholar
  81. Richelle M, Bortlik K, Liardet S et al (2002) A food-based formulation provides lycopene with the same bioavailability to humans as that from tomato paste. J Nutr 132:404–408PubMedGoogle Scholar
  82. Riso P, Brusamolino A, Martinetti A et al (2006) Effect of a tomato drink intervention on insulin-like growth factor (IGF)-1 serum levels in healthy subjects. Nutr Cancer 55:157–1562PubMedCrossRefGoogle Scholar
  83. Rittmaster RS (2008) 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. Best Pract Res Clin Endocrinol Metab 22:389–402PubMedCrossRefGoogle Scholar
  84. Satia JA, Littman A, Slatore CG et al (2009) Long-term use of β-carotene, retinol, lycopene, and lutein supplements and lung cancer risk: results from the VITamins and lifestyle (VITAL) study. Am J Epidemiol 169:815–828PubMedCrossRefGoogle Scholar
  85. Schwarz S, Obermuller-Jevic UC, Hellmis E et al (2008) Lycopene inhibits disease progression in patients with benign prostate hyperplasia. J Nutr 138:49–53PubMedGoogle Scholar
  86. Sherr CJ (1995) D-type cyclins. Trends Biochem Sci 20:187–190PubMedCrossRefGoogle Scholar
  87. Signorello LB, Kuper H, Lagiou P et al (2000) Lifestyle factors and insulin-like growth factor 1 levels among elderly men. Eur J Cancer Prev 9:173–178PubMedCrossRefGoogle Scholar
  88. Siler U, Barella L, Spitzer V et al (2004) Lycopene and vitamin E interfere with autocrine/paracrine loops in the Dunning prostate cancer model. FASEB J 18:1019–1021PubMedGoogle Scholar
  89. Stahl W, Sies H (1992) Uptake of lycopene and its geometrical isomers is greater from heat-processed than from unprocessed tomato juice in humans. J Nutr 122:2161–2166PubMedGoogle Scholar
  90. Talalay P (2000) Chemoprotection against cancer by induction of phase 2 enzymes. Biofactors 12:5–11PubMedCrossRefGoogle Scholar
  91. Talalay P, Fahey JW (2001) Phytochemicals from cruciferous plants protect against cancer by modulating carcinogen metabolism. J Nutr 131:3027S–3033SPubMedGoogle Scholar
  92. Talegawkar SA, Johnson EJ, Carithers TC et al (2008) Carotenoid intakes, assessed by food-frequency questionnaires (FFQs), are associated with serum carotenoid concentrations in the Jackson Heart Study: validation of the Jackson Heart Study Delta NIRI Adult FFQs. Public Health Nutr 11:989–997PubMedCrossRefGoogle Scholar
  93. Taylor PR, Li B, Dawsey SM et al (1994) Prevention of esophageal cancer: the nutrition intervention trials in Linxian, China. Linxian Nutrition Intervention Trials Study Group. Cancer Res 54:2029S–2031SPubMedGoogle Scholar
  94. Teixeira C, Pratt MAC (1997) CDK2 is a target for retinoic acid–mediated growth inhibition in MCF-7 human breast cancer cells. Mol Endocrinol 11:1191–1202PubMedCrossRefGoogle Scholar
  95. Temple NJ, Gladwin KK (2003) Fruit, vegetables, and the prevention of cancer: research challenges. Nutrition 19:467–470PubMedCrossRefGoogle Scholar
  96. Tran CD, Diorio C, Berube S et al (2006) Relation of insulin-like growth factor (IGF) I and IGF-binding protein 3 concentrations with intakes of fruit, vegetables, and antioxidants. Am J Clin Nutr 84:1518–1526PubMedGoogle Scholar
  97. van Poppel G (1993) Carotenoids and cancer: An update with emphasis on human intervention studies. Eur J Cancer 29A:1335–1344PubMedCrossRefGoogle Scholar
  98. Voskuil DW, Vrieling A, Korse CM et al (2008) Effects of lycopene on the insulin-like growth factor (IGF) system in premenopausal breast cancer survivors and women at high familial breast cancer risk. Nutr Cancer 60:342–353PubMedCrossRefGoogle Scholar
  99. Vrieling A, Voskuil DW, Bueno de Mesquita HB et al (2004) Dietary determinants of circulating insulin-like growth factor (IGF)-I and IGF binding proteins 1, -2 and -3 in women in the Netherlands. Cancer Causes Control 15:787–796PubMedCrossRefGoogle Scholar
  100. Vrieling A, Voskuil DW, Bonfrer JM et al (2007) Lycopene supplementation elevates circulating insulin-like growth factor binding protein-1 and -2 concentrations in persons at greater risk of colorectal cancer. Am J Clin Nutr 86:1456–1462PubMedGoogle Scholar
  101. Walfisch Y, Walfisch S, Agbaria R et al (2003) Lycopene in serum, skin and adipose tissues after tomato-oleoresin supplementation in patients undergoing haemorrhoidectomy or peri-anal fistulotomy. Br J Nutr 90:759–766.PubMedCrossRefGoogle Scholar
  102. Walfisch S, Walfisch Y, Kirilov E et al (2007) Tomato lycopene extract supplementation decreases insulin-like growth factor-I levels in colon cancer patients. Eur J Cancer Prev 16:298–303PubMedCrossRefGoogle Scholar
  103. Wang AH, Zhang LS (2007) Effect of lycopene on the proliferation of MCF-7 and MDA-MB-231 cells. Sichuan Da Xue Xue Bao Yi Xue Ban 38:958–960PubMedGoogle Scholar
  104. Wang C, Baumgartner RN, Yang D et al (2009) No evidence of association between breast cancer risk and dietary carotenoids, retinols, vitamin C and tocopherols in Southwestern Hispanic and non-Hispanic White women. Breast Cancer Res Treat 114:137–145PubMedCrossRefGoogle Scholar
  105. Watts CK, Sweeney KJ, Warlters A et al (1994) Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells. Breast Cancer Res Treat 31:95–105PubMedCrossRefGoogle Scholar
  106. Wu WB, Chiang HS, Fang JY et al (2007) Inhibitory effect of lycopene on PDGF-BB-induced signalling and migration in human dermal fibroblasts: a possible target for cancer. Biochem Soc Trans 35:1377–1378PubMedCrossRefGoogle Scholar
  107. Zhou Q, Stetler Stevenson M, Steeg PS (1997) Inhibition of cyclin D expression in human breast carcinoma cells by retinoids in vitro. Oncogene 15:107–115PubMedCrossRefGoogle Scholar
  108. Ziouzenkova O, Orashanu G, Sukhova G et al (2007) Asymmetric cleavage of β-carotene yields a transcriptional repressor of RXR and PPAR responses. Mol Endocrinol 21:77–88PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Joseph Levy
    • 1
    • 2
    Email author
  • Shlomo Walfisch
    • 3
  • Andrea Atzmon
    • 3
  • Keren Hirsch
    • 3
  • Marina Khanin
    • 3
  • Karin Linnewiel
    • 3
  • Yael Morag
    • 3
  • Hagar Salman
    • 3
  • Anna Veprik
    • 3
  • Michael Danilenko
    • 3
  • Yoav Sharoni
    • 3
  1. 1.Department of Clinical BiochemistryFaculty of Health Sciences, Ben-Gurion UniversityBeer-ShevaIsrael
  2. 2.Soroka Medical Center of Kupat HolimBeer-ShevaIsrael
  3. 3.Department of Clinical Biochemistry and the Colorectal UnitFaculty of Health Sciences, Ben-Gurion University and Soroka Medical Center of Kupat HolimBeer-ShevaIsrael

Personalised recommendations